Subscribe
The latest psychology and neuroscience discoveries.
My Account
  • Mental Health
  • Social Psychology
  • Cognitive Science
  • Psychopharmacology
  • Neuroscience
  • About
No Result
View All Result
PsyPost
PsyPost
No Result
View All Result
Home Exclusive Mental Health

Psilocybin shows promise in OCD treatment — even without the psychedelic “trip”

by Eric W. Dolan
June 13, 2023
in Mental Health, Psilocybin
(Photo credit: Adobe Stock)

(Photo credit: Adobe Stock)

Share on TwitterShare on Facebook
Stay on top of the latest psychology findings: Subscribe now!

Blocking the subjective psychedelic effects of psilocybin does not appear to interfere with the substance’s ability to potentially help with obsessive behaviors, according to new research published in Translational Psychiatry. The findings contribute to the growing body of research on the clinical application of psychedelics in psychiatry and highlight the need for further investigation in clinical trials to evaluate the efficacy and safety of psilocybin in the treatment of obsessive-compulsive disorder (OCD).

Psilocybin is a naturally occurring psychedelic compound found in certain species of mushrooms, often referred to as “magic mushrooms.” It is a serotonergic hallucinogen that can produce profound alterations in perception, mood, and cognition.

Psilocybin has shown promise as a potential therapeutic agent for various mental health conditions, including depression, anxiety, post-traumatic stress disorder (PTSD), and addiction. Preliminary studies have suggested that psilocybin-assisted therapy can have long-lasting positive effects on mental well-being and quality of life.

OCD is a debilitating disorder characterized by uncontrollable thoughts and repetitive behaviors. While current treatments such as antidepressants and cognitive behavioral therapy can be effective, a significant number of patients do not respond to these treatments, highlighting the need for alternative therapeutic options.

“We are very interested in the potential of psychedelic drugs to treat psychiatric disorders, particularly in patients who do not respond well to standard medications,” explained study author Bernard Lerer, a psychiatry professor at Hebrew University. “For that reason, we founded the Hadassah BrainLabs Center for Psychedelic Research where we do extensive research on psychedelic drugs. Obsessive-compulsive disorder (OCD) is one of the conditions in which a high proportion of patients do not respond well to standard treatment – at least a third.”

“There is preliminary evidence from studies in patients that psilocybin can help patients with OCD. But psilocybin induces a psychedelic trip and this requires special management. We think that psilocybin could help patients with OCD without the trip. How do we achieve this?”

“We have shown in a different study that the medication, buspirone, which is used to treat anxiety, blocks a mouse equivalent of the psychedelic trip and another researcher has shown that it does so in humans,” Lerer explained. “We wanted to find out whether psilocybin would be effective in a mouse model for anti-obsessional effects – marble burying – and whether it would do so even in the presence of buspirone, which blocks the trip.”

The study utilized a preclinical model called the marble-burying test, which measures the propensity of rodents to dig and cover objects placed in their cages. This test is considered to have reasonable predictive validity for identifying drugs that may be effective in treating OCD. Previous studies using the marble-burying test have shown that psilocybin and other psychedelic compounds reduce marble burying in mice, suggesting their potential therapeutic effect in OCD.

In this study, the researchers aimed to examine the role of serotonin 2A (5-HT2A) receptors, which are the primary target of psilocybin, in its effect on marble burying. They also sought to investigate the involvement of serotonin 1A (5-HT1A) receptors, another serotonin receptor subtype, in psilocybin’s effect. Additionally, the study explored the impact of different administration methods and the persistence of the anti-marble-burying effect after 7 days.

The researchers conducted the experiments using male mice. They administered various drugs, including psilocybin, escitalopram (an SSRI), and other compounds that selectively target 5-HT2A and 5-HT1A receptors, through intraperitoneal injection. The mice underwent the marble-burying test, where the number of marbles buried by the mice was measured after drug administration. They also performed an open field test to assess locomotor activity and a head twitch response test, which is associated with psychedelic effects.

The results of the study showed that mice treated with psilocybin buried significantly fewer marbles compared to the control group. This reduction in marble burying was similar to the effect observed with escitalopram, indicating that psilocybin may have a similar therapeutic effect as antidepressant medication in the treatment of OCD.

Interestingly, blocking the 5-HT2A receptors using a selective antagonist (known as M100907) did not prevent the anti-marble-burying effect of psilocybin, suggesting that this effect is not mediated solely by 5-HT2A receptor activation. On the other hand, buspirone, a 5-HT1A receptor agonist, blocked the effects of psilocybin on the head twitch response test, but did not impeding its psilocybin’s effect on marble burying.

“Mice administered psilocybin with buspirone performed as well on the marble burying test as mice administered psilocybin without buspirone,” Lerer told PsyPost. “The results were clear even though buspirone prevented the trip. Our findings mean that we could potentially treat patients with OCD with the two drugs together and help their OCD without causing them to have a psychedelic trip. That would be very important clinically.”

The study also investigated different administration methods and found that psilocybin administered as a staggered dose had a similar effect on marble burying as a single bolus injection. Additionally, the anti-marble-burying effect of psilocybin persisted for at least 7 days, indicating a potential long-lasting therapeutic effect.

“There is an important role for psychedelic drugs to treat psychiatric disorders that are not helped by standard treatment,” Lerer said. “Worldwide millions of people are in need of alternative treatment. Our study suggests that there is a way to treat OCD with psilocybin without the patient having to undergo a full scale psychedelic trip. Planning is under way for a clinical trial to test this suggestion.”

The study provides further evidence for the potential therapeutic effect of psilocybin in OCD using a preclinical model. But some limitations should be noted. The study used mice as an animal model to assess the effects of buspirone and psilocybin on marble burying behavior. While animal models can provide valuable preliminary data, the results may not directly translate to humans.

“Like all discoveries in mice, the ultimate test is in people,” Lerer said. “However, buspirone has already been shown to reduce the psychedelic trip in humans so there is already support from human studies.”

“People interested in learning more about Psychedelic Medicine can register for Psychedelic Medicine – Israel 2023, which will be held in Tel Aviv on December 10-13, 2023 and will cover all cutting edge areas of psychedelic medicine,” Lerer added.

The study, “Effect of psilocybin on marble burying in ICR mice: role of 5-HT1A receptors and implications for the treatment of obsessive-compulsive disorder“, was authored by Sandeep Singh, Alexander Botvinnik, Orr Shahar, Gilly Wolf, Corel Yakobi, Michal Saban, Adham Salama, Amit Lotan, Bernard Lerer, and Tzuri Lifschytz.

TweetSendScanShareSendPinShareShareShareShareShare

RELATED

Ketamine repairs reward circuitry to reverse stress-induced anhedonia
Mental Health

Can sunshine make you happier? A massive study offers a surprising answer

July 9, 2025

Can something as simple as the weather really change how we feel about our lives? A sweeping new study from China explores the long-debated link between sunshine and well-being, using data from thousands of people across the country.

Read moreDetails
Ketamine repairs reward circuitry to reverse stress-induced anhedonia
Anxiety

Virtual reality meditation eases caregiver anxiety during pediatric hospital stays, with stronger benefits for Spanish speakers

July 9, 2025

Researchers at Stanford found that a six-minute guided meditation delivered through a VR headset lowered anxiety levels in parents of hospitalized children. The intervention outperformed standard relaxation methods, with Spanish-speaking caregivers experiencing the greatest benefit.

Read moreDetails
Ketamine repairs reward circuitry to reverse stress-induced anhedonia
Autism

Prenatal exposure to “forever chemicals” linked to autistic traits in children, study finds

July 9, 2025

Children exposed to high levels of PFAS during early pregnancy may face an increased risk of autistic traits by age four, especially if they also have a higher inherited risk for autism, according to new findings.

Read moreDetails
Ketamine repairs reward circuitry to reverse stress-induced anhedonia
Depression

Ketamine repairs reward circuitry to reverse stress-induced anhedonia

July 9, 2025

New research shows a single low, non-anesthetic dose of ketamine revived pleasure seeking in chronically stressed mice by restoring weakened excitatory synapses onto nucleus accumbens dopamine D1 neurons, pinpointing a circuit mechanism for the drug’s rapid antidepressant effect.

Read moreDetails
Psychedelic drug DOI activates specific brain neurons to ease anxiety
Depression

Choline imbalance in the brain linked to with cognitive symptoms in young depression patients

July 8, 2025

Researchers have identified metabolic differences in the brains of young adults with depression who also experience cognitive impairment. The study sheds light on how chemical imbalances in key brain regions may contribute to thinking and memory problems in depression.

Read moreDetails
Epigenetic age acceleration moderates the link between loneliness and chronic health conditions
Dementia

Sedentary time linked to faster brain aging in older adults, study finds

July 8, 2025

A large observational study found that sedentary time in older adults predicted worsening memory, shrinking brain structures, and slower mental processing over seven years, regardless of how physically active participants were.

Read moreDetails
The most popular dementia videos on TikTok tend to have the lowest quality, study find
Addiction

People with short-video addiction show altered brain responses during decision-making

July 8, 2025

People who frequently use short-video apps like TikTok may show reduced loss sensitivity and impulsive decision-making, according to a new neuroimaging study that links addictive use patterns to changes in brain activity during risky choices.

Read moreDetails
Probiotic supplements may improve working memory
ADHD

Probiotics show promise for reducing hyperactivity in young children with autism and ADHD

July 7, 2025

Researchers are exploring the gut-brain connection to support children with autism and ADHD. A new clinical trial reports a specific probiotic blend reduced parent ratings of hyperactivity and impulsivity in younger children, suggesting a potential new therapeutic target.

Read moreDetails

SUBSCRIBE

Go Ad-Free! Click here to subscribe to PsyPost and support independent science journalism!

STAY CONNECTED

LATEST

Can sunshine make you happier? A massive study offers a surprising answer

New study links why people use pornography to day-to-day couple behavior

Virtual reality meditation eases caregiver anxiety during pediatric hospital stays, with stronger benefits for Spanish speakers

Fascinating new advances in psychedelic science reveal how they may heal the mind

Dysfunction within the sensory processing cortex of the brain is associated with insomnia, study finds

Prenatal exposure to “forever chemicals” linked to autistic traits in children, study finds

Ketamine repairs reward circuitry to reverse stress-induced anhedonia

Neuroscientists decode how people juggle multiple items in working memory

         
       
  • Contact us
  • Privacy policy
  • Terms and Conditions
[Do not sell my information]

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

Subscribe
  • My Account
  • Cognitive Science Research
  • Mental Health Research
  • Social Psychology Research
  • Drug Research
  • Relationship Research
  • About PsyPost
  • Contact
  • Privacy Policy